International Union against Tuberculosis and Lung Disease, The Union, South-East Asia Regional Office, New Delhi, India.
PLoS One. 2011;6(11):e26659. doi: 10.1371/journal.pone.0026659. Epub 2011 Nov 2.
Revised National TB Control Programme (RNTCP), Andhra Pradesh, India. There is limited information on whether MDR-TB suspects are identified, undergo diagnostic assessment and are initiated on treatment according to the programme guidelines.
To assess i) using the programme definition, the number and proportion of MDR-TB suspects in a large cohort of TB patients on first-line treatment under RNTCP ii) the proportion of these MDR-TB suspects who underwent diagnosis for MDR-TB and iii) the number and proportion of those diagnosed as MDR-TB who were successfully initiated on treatment.
A retrospective cohort analysis, by reviewing RNTCP records and reports, was conducted in four districts of Andhra Pradesh, India, among patients registered for first line treatment during October 2008 to December 2009.
Among 23,999 TB patients registered for treatment there were 559 (2%) MDR-TB suspects (according to programme definition) of which 307 (55%) underwent diagnosis and amongst these 169 (55%) were found to be MDR-TB. Of the MDR-TB patients, 112 (66%) were successfully initiated on treatment. Amongst those eligible for MDR-TB services, significant proportions are lost during the diagnostic and treatment initiation pathway due to a variety of operational challenges. The programme needs to urgently address these challenges for effective delivery and utilisation of the MDR-TB services.
印度安得拉邦修订国家结核控制规划（RNTCP）。关于耐多药结核疑似患者是否根据方案指南得到识别、接受诊断评估并开始接受治疗，相关信息有限。
评估 i）根据方案定义，在 RNTCP 下接受一线治疗的大量结核患者中耐多药结核疑似患者的数量和比例；ii）这些耐多药结核疑似患者中接受耐多药结核诊断的比例；iii）诊断为耐多药结核的患者中成功开始治疗的数量和比例。
在印度安得拉邦的四个地区，对 2008 年 10 月至 2009 年 12 月期间登记接受一线治疗的患者进行了回顾性队列分析，查阅了 RNTCP 记录和报告。
在登记接受治疗的 23999 例结核患者中，有 559 例（2%）为耐多药结核疑似患者（根据方案定义），其中 307 例（55%）接受了诊断，其中 169 例（55%）被诊断为耐多药结核。在耐多药结核患者中，有 112 例（66%）成功开始治疗。在有资格获得耐多药结核服务的患者中，由于各种操作挑战，在诊断和治疗启动过程中大量患者流失。方案需要紧急解决这些挑战，以有效提供和利用耐多药结核服务。
